TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9609638

Group type: EXPERIMENTAL
Intervention: 3DCRT (78 Gy conformal radiotherapy)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conven-RT (70 Gy conventional radiotherapy)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 101
Study: 2566160

Group type: EXPERIMENTAL
Intervention: Broxaterol (new beta 2-agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salbutamol (control)
Number of subjects: 0
Study: 334356

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorotrianisene
Number of subjects: 0
Study: 31401140

Group type: EXPERIMENTAL
Intervention: Glecaprevir and Pibrentasvir for 12 weeks (group A)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Glecaprevir and Pibrentasvir for 16 weeks (group B)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Glecaprevir and Pibrentasvir plus Ribavirin for 12 weeks (group C)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Glecaprevir and Pibrentasvir for 16 weeks (group D)
Number of subjects: 177
Study: 29265085

Group type: EXPERIMENTAL
Intervention: Xeomin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Botox
Number of subjects: 64
Study: 25555173

Group type: EXPERIMENTAL
Intervention: loteprednol etabonate 0.5%/tobramycin 0.3% (Zylet)
Number of subjects: 32

Group type: COMPARATOR
Intervention: dexamethasone 0.1%/tobramycin 0.3% (Tobradex)
Number of subjects: 32
Study: 23706046

Group type: EXPERIMENTAL
Intervention: Sodium nitrite (64 nmol/kg/min)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sodium nitrite infusion
Number of subjects: 18
Study: 22007990

Group type: EXPERIMENTAL
Intervention: Tipranavir/ritonavir (TPV/r) 500/200 mg twice daily
Number of subjects: 39

Group type: COMPARATOR
Intervention: Darunavir/ritonavir (DRV/r) 600/100 mg twice daily
Number of subjects: 39
Study: 19768804

Group type: EXPERIMENTAL
Intervention: 2.5 mg nebulized rhDNase twice daily for 2 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16796545

Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids (SS)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Nebulized budesonide (ICS)
Number of subjects: 6
Study: 15558250

Group type: EXPERIMENTAL
Intervention: Anodal cerebellar stimulation (high-voltage electric stimuli with an anode on the ipsilateral mastoid process and a cathode over the contralateral process)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Reversed current of conditioning stimulus
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Same (anodal) conditioning stimuli
Number of subjects: 9
Study: 11143509

Group type: EXPERIMENTAL
Intervention: Longmire‐Interposition with pouch
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Longmire‐Interposition without pouch
Number of subjects: 49

Group type: COMPARATOR
Intervention: Roux‐en‐Y‐reconstruction
Number of subjects: 49
Study: 9266780

Group type: EXPERIMENTAL
Intervention: Warfarin therapy (INR 2.7 +/‐ 1.3)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin (INR 1.3 +/‐ 0.08)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Moderate-intensity warfarin (INR 2.3 +/‐ 1.1)
Number of subjects: 76
Study: 8277435

Group type: EXPERIMENTAL
Intervention: 4% potassium nitrate-zinc oxide eugenol temporary cement
Number of subjects: 0
Study: 3539165

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30632718

Group type: EXPERIMENTAL
Intervention: Reinforced antenatal counseling
Number of subjects: 404

Group type: COMPARATOR
Intervention: Routine antenatal counseling
Number of subjects: 404
Study: 26980363

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 396

Group type: COMPARATOR
Intervention: Education control
Number of subjects: 396
Study: 25324541

Group type: EXPERIMENTAL
Intervention: Self-report of smoking validated by serum cotinine levels
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Never or past smokers
Number of subjects: 626

Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 626
Study: 22545431

Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride dentifrice
Number of subjects: 100

Group type: COMPARATOR
Intervention: Regular control paste
Number of subjects: 100
Study: 20452432

Group type: EXPERIMENTAL
Intervention: 1.2 microg antigen dose
Number of subjects: 3697

Group type: EXPERIMENTAL
Intervention: 1.2 microg paediatric dose
Number of subjects: 3697

Group type: EXPERIMENTAL
Intervention: FSME‐IMMUN paediatric vaccine formulation
Number of subjects: 3697
Study: 17565457

Group type: EXPERIMENTAL
Intervention: Cefepime 2 g iv/12 h plus metronidazole 500 mg/8 h
Number of subjects: 122

Group type: COMPARATOR
Intervention: Imipenem-cilastatin 500 mg iv/6 h
Number of subjects: 122
Study: 16022166

Group type: EXPERIMENTAL
Intervention: Adaptive covariate adjustment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Covariate transformation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regression modeling approach
Number of subjects: 0
Study: 12117888

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (EPT)
Number of subjects: 111

Group type: COMPARATOR
Intervention: No endoscopic intervention (non-EPT)
Number of subjects: 111
Study: 9935011

Group type: EXPERIMENTAL
Intervention: Successful angioplasty with abrupt vessel closure
Number of subjects: 3899
Study: 7557868

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg per os once a week for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2228932

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Active medication groups (Alprazolam and Imipramine combined)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 29737255

Group type: EXPERIMENTAL
Intervention: Screening for Primary Aldosteronism (PA) in hypertensive patients with spontaneous or diuretic-induced hypokalemia and resistant hypertension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Screening for Primary Aldosteronism (PA) in all hypertensive patients
Number of subjects: 0
Study: 28460449

Group type: EXPERIMENTAL
Intervention: Laparoscopic radical cystectomy (LRC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC)
Number of subjects: 60
Study: 26220257

Group type: EXPERIMENTAL
Intervention: Foot reflexology treatment for 20-30 minutes before vaccination
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no reflexology treatment)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Foot reflexology treatment
Number of subjects: 60
Study: 24693675

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (Rabeprazole 20 mg once a day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Histamine H2 receptor antagonist (Famotidine 20 mg twice a day)
Number of subjects: 18
Study: 21205246

Group type: EXPERIMENTAL
Intervention: Early hemicraniectomy within 48 hours after symptom onset
Number of subjects: 160

Group type: COMPARATOR
Intervention: Maximum conservative treatment alone
Number of subjects: 160
Study: 19663519

Group type: COMPARATOR
Intervention: TRC4186 250-2500 mg single dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: TRC4186 500-2000 mg multiple doses (twice daily for 6 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TRC4186 500 mg (fasted) vs 500 mg (fed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TRC4186 500 mg followed by 1000 mg after 7-day washout in elderly subjects
Number of subjects: 0
Study: 16441520

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional amphotericin B (CAB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Voriconazole vs. CAB
Number of subjects: 0
Study: 15037334

Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 307

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 307
Study: 11232870

Group type: EXPERIMENTAL
Intervention: 10% PVP-I
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 70% ethyl alcohol
Number of subjects: 5

Group type: COMPARATOR
Intervention: Plain liquid soap
Number of subjects: 5

Group type: COMPARATOR
Intervention: 4% chlorhexidine
Number of subjects: 5
Study: 9429043

Group type: EXPERIMENTAL
Intervention: 0.05 mg.kg‐1 rocuronium, 3 min before 2 mg.kg‐1 succinylcholine (ROC‐3 min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.05 mg.kg‐1 rocuronium, 1.5 min before 2 mg.kg‐1 succinylcholine (ROC‐1.5 min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No rocuronium before 2 mg.kg‐1 succinylcholine (NO ROC)
Number of subjects: 60
Study: 8504594

Group type: EXPERIMENTAL
Intervention: Modified Hardinge approach
Number of subjects: 100

Group type: COMPARATOR
Intervention: Transtrochanteric lateral approach
Number of subjects: 100
Study: 3622595

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 122

Group type: COMPARATOR
Intervention: Bromoergocriptine
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Bromoergocriptine plus Domperidone
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 29935641

Group type: EXPERIMENTAL
Intervention: 2% O2 from D3 to D5
Number of subjects: 203

Group type: COMPARATOR
Intervention: 5% O2 from D1 to D5
Number of subjects: 203
Study: 27035853

Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine 266 mg
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine
Number of subjects: 116
Study: 24355800

Group type: EXPERIMENTAL
Intervention: Multiparametric cardiovascular magnetic resonance (CMR) assessment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Coronary angiography
Number of subjects: 48
Study: 24033812

Group type: EXPERIMENTAL
Intervention: Apically positioned flap (APF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Modified Widman flap (MWF)
Number of subjects: 30
Study: 20116964

Group type: EXPERIMENTAL
Intervention: Patient feedback performance improvement intervention (12 weeks)
Number of subjects: 118

Group type: COMPARATOR
Intervention: No intervention (control group, 12 weeks)
Number of subjects: 118
Study: 17712347

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/day for 10 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Ziprasidone 80 mg/day for 10 days
Number of subjects: 29
Study: 16357337

Group type: EXPERIMENTAL
Intervention: Thalamic deep brain stimulation (DBS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unilateral thalamotomy in the cerebellar thalamus
Number of subjects: 0
Study: 15022145

Group type: EXPERIMENTAL
Intervention: No planned interventions (naturalistic observation)
Number of subjects: 271
Study: 11738299

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) users
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) nonusers
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Carvedilol treatment with ASA
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Carvedilol treatment without ASA
Number of subjects: 293

Group type: COMPARATOR
Intervention: Placebo treatment with ASA
Number of subjects: 293

Group type: COMPARATOR
Intervention: Placebo treatment without ASA
Number of subjects: 293
Study: 9033324

Group type: EXPERIMENTAL
Intervention: Heparin loading dose of 300 U/kg followed by 1 U/mL of heparin in the prime (low-dose group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Heparin loading dose of 300 U/kg followed by 3 U/mL of heparin in the prime (high-dose group)
Number of subjects: 48
Study: 8285609

Group type: EXPERIMENTAL
Intervention: Rufloxacin 400 mg on day 1 and 200 mg daily for 9 days (n = 64)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Rufloxacin 300 mg on day 1 and 150 mg daily for 9 days (n = 63)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Amoxicillin 500 mg three times a day for 10 days (n = 65)
Number of subjects: 192
Study: 3300566

Group type: EXPERIMENTAL
Intervention: Hypnosis with relaxation therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control session
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Follow-up examination
Number of subjects: 15
Study: 30365341

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 27580889

Group type: EXPERIMENTAL
Intervention: Baseline tumor volume (≥15cc)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Baseline tumor volume (<15cc)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Large tumors (≥15cc)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Cabozantinib
Number of subjects: 497
Study: 25565416

Group type: EXPERIMENTAL
Intervention: FitBack intervention
Number of subjects: 597

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 597

Group type: COMPARATOR
Intervention: Alternative care group
Number of subjects: 597
Study: 23891062

Group type: EXPERIMENTAL
Intervention: Self-administered 50% nitrous oxide
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional infiltrative anaesthesia with 1% prilocaine hydrochloride
Number of subjects: 100
Study: 21087856

Group type: EXPERIMENTAL
Intervention: Interferon α2b (IFN)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Serial determination of S100B
Number of subjects: 211
Study: 19247544

Group type: EXPERIMENTAL
Intervention: Fitness centre-based exercise programme (supervised by a personal trainer, 3 times per week for 12 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Home-based exercise programme (unsupervised at home, similar exercise programme)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Fitness centre-based exercise programme
Number of subjects: 62

Group type: COMPARATOR
Intervention: Home-based exercise programme
Number of subjects: 62
Study: 17254453

Group type: EXPERIMENTAL
Intervention: IVIG 1 g/kg
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: IVIG 2 g/kg
Number of subjects: 242
Study: 15968598

Group type: EXPERIMENTAL
Intervention: Patients with CAD
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Patients with CAD with decreased LVEF (dEF)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Patients with CAD with normal LVEF (nEF) and an average filling rate (AFR) <= 1.04 EDV/s
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Total CAD group
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Patients with CAD with normal LVEF (nEF)
Number of subjects: 69
Study: 11824887

Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) + Interferon-alpha (IFN-alpha)
Number of subjects: 61
Study: 9625835

Group type: EXPERIMENTAL
Intervention: Serum p53 antibodies positive patients (33 out of 57)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Tumor markers (CEA, SCC-Ag, CYFRA21-1)
Number of subjects: 57
Study: 8003109

Group type: COMPARATOR
Intervention: Glucose only (2 mg/kg BW/min)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Glucose and xylitol mixture (1:1; 2 mg/kg BW/min)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Glucose-containing electrolyte solution (0.8 mg/kg BW/min)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Glucose (4 mg/kg BW/min)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Glucose-xylitol mixture (4 mg/kg BW/min)
Number of subjects: 23
Study: 3582908

Group type: EXPERIMENTAL
Intervention: Oral nifedipine (10‐30 mg t.i.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Distal esophageal contraction pressures
Number of subjects: 20
Study: 29561290

Group type: EXPERIMENTAL
Intervention: CM for tobacco smoking
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CM for alcohol
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CM for smoking
Number of subjects: 34

Group type: COMPARATOR
Intervention: NC for alcohol and tobacco smoking
Number of subjects: 34
Study: 25423875

Group type: EXPERIMENTAL
Intervention: MICA-UKA (Group A)
Number of subjects: 87

Group type: COMPARATOR
Intervention: MI-UKA (Group B)
Number of subjects: 87
Study: 23943258

Group type: EXPERIMENTAL
Intervention: Web-mode administration of SF-36
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Web-mode administration of UCLA-PCI
Number of subjects: 245

Group type: COMPARATOR
Intervention: Paper-mode administration of SF-36
Number of subjects: 245

Group type: COMPARATOR
Intervention: Paper-mode administration of UCLA-PCI
Number of subjects: 245
Study: 21773723

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee with high chlorogenic acid content
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 39

Group type: COMPARATOR
Intervention: Decaffeinated coffee with regular chlorogenic acid
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 20403516

Group type: EXPERIMENTAL
Intervention: Training group (proficient in laparoscopic suturing)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not proficient in laparoscopic suturing)
Number of subjects: 20
Study: 18544005

Group type: EXPERIMENTAL
Intervention: Tetrabenazine treatment for 2 years
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Tetrabenazine treatment for a mean duration of 19 months
Number of subjects: 77
Study: 16402873

Group type: EXPERIMENTAL
Intervention: Family-based intervention for preschoolers at risk for conduct problems
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 92
Study: 12578937

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (Cr)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10551653

Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 80

Group type: COMPARATOR
Intervention: CsA
Number of subjects: 80
Study: 8686245

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Orimethen
Number of subjects: 176
Study: 1725540

Group type: EXPERIMENTAL
Intervention: nisoldipine 10 mg b.i.d.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: nifedipine 10 mg t.i.d.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: nifedipine 20 mg t.i.d.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: diltiazem 60 mg t.i.d.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: diltiazem 120 mg t.i.d.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: verapamil 40 mg q.i.d.
Number of subjects: 80
Study: 6358886

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase therapy
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 250
Study: 30955358

Group type: EXPERIMENTAL
Intervention: Intervention group (involved in meals rehabilitation program)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (usual community aged care)
Number of subjects: 123
Study: 29477151

Group type: EXPERIMENTAL
Intervention: 5% CaP supplementation
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 10% CaP supplementation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control without CaP supplementation
Number of subjects: 54
Study: 26856808

Group type: EXPERIMENTAL
Intervention: Bolus administration (40% of daily dose split into four equal boli applied every six hours, with 60% as background continuous infusion)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Continuous infusion (same pump parameters as during baseline evaluation)
Number of subjects: 10
Study: 25390455

Group type: EXPERIMENTAL
Intervention: Intravenous thiamine (200 mg)
Number of subjects: 17
Study: 22119706

Group type: EXPERIMENTAL
Intervention: Pediatric Motor Activity Log - Quality of Movement (PMAL-QOM)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pediatric Motor Activity Log - Amount of Use (PMAL-AOU)
Number of subjects: 41
Study: 20175242

Group type: EXPERIMENTAL
Intervention: Modified orotracheal intubation (Group M)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional orotracheal intubation (Group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (Group M and Group C)
Number of subjects: 60
Study: 17641566

Group type: EXPERIMENTAL
Intervention: Genuine acupuncture
Number of subjects: 135

Group type: COMPARATOR
Intervention: Sham acupuncture (Streitberger needle)
Number of subjects: 135
Study: 15613571

Group type: EXPERIMENTAL
Intervention: Morphine (100 microg/kg plus 10 microg/kg/h)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 126
Study: 12586256

Group type: EXPERIMENTAL
Intervention: Percutaneous mechanical mitral commissurotomy (PMMC)
Number of subjects: 173
Study: 10497668

Group type: EXPERIMENTAL
Intervention: Minolest (16.5 g/day)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 7590572

Group type: EXPERIMENTAL
Intervention: Effervescent tablet of sucralfate (2.0 g twice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Granular formulation of sucralfate (2.0 g twice daily)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both treatment groups (effervescent and granular)
Number of subjects: 50
Study: 1720917

Group type: EXPERIMENTAL
Intervention: Encainide or flecainide
Number of subjects: 2371

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2371
Study: 7005682

Group type: EXPERIMENTAL
Intervention: Simple protective isolation (437 days)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard hospital care (611 days)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Simple protective isolation
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard hospital care
Number of subjects: 43
Study: 30846338

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 0
Study: 29193819

Group type: EXPERIMENTAL
Intervention: Selexipag (maximum of 1,600 μg twice daily)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 74